Anti-CGRP monoclonal antibodies: breakthrough in migraine therapeutics

Abstract

Migraine is considered as one of the most debilitating neurological disorders but the success of the anti-calcitonin gene-related peptide (CGRP) therapies marks a new era in the treatment of migraine and has paved way for further research into the exact pathophysiology of migraine. Here, the authors discuss their literature review on the anti-CGRP therapies to examine the pathophysiology of migraine, with a focus on the possible role of CGRP and the safety and efficacy of monoclonal antibodies targeting it.